21st Jul 2005 13:19
Pfizer Statement on SUTENT Regulatory Submission NEW YORK, July 21 -- Although Pfizer does not normally comment in advance on the expected timing of regulatory submissions, it issued the following statement today to address recent analyst comments regarding the regulatory filing of SUTENT in the U.S.: Pfizer plans to file its investigational new drug SUTENT (sunitinib malate) for metastatic renal cell and gastrointestinal stromal cancer indications during August. SOURCE Pfizer Inc 07/21/2005 /CONTACT: Paul Fitzhenry of Pfizer, +1-212-733-4637/ /Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call 972-392-0888./ /Web site: http://www.pfizer.com / (PFE) ENDPFIZER INCRelated Shares:
PFZ.L